NewAmsterdam Pharma Company NV Ordinary Shares logo

NewAmsterdam Pharma Company NV Ordinary SharesNASDAQ: NAMS

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Netherlands

IPO:

09 February 2021

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.87 B
-22%vs. 3y high
80%vs. sector
-vs. 3y high
-vs. sector
-36%vs. 3y high
82%vs. sector
-82%vs. 3y high
93%vs. sector

Price

regular market | 5 min ago
$20.25+$0.24(+1.22%)

Dividend

No data over the past 3 years
$29.11 M$1.61 M
$29.11 M-$16.65 M

Analysts recommendations

Institutional Ownership

NAMS Latest News

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
globenewswire.com28 October 2024 Sentiment: POSITIVE

NAARDEN, The Netherlands and MIAMI, Oct. 28, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present additional safety and efficacy data from the pivotal Phase 3 BROOKLYN study evaluating obicetrapib in patients with Heterozygous Familial Hypercholesterolemia in a late-breaking oral presentation at the 2024 American Heart Association (AHA) Scientific Sessions, taking place November 16 – 18, 2024 in Chicago, Illinois. Additionally, NewAmsterdam announced that company management will participate in the Jefferies London Healthcare Conference, taking place November 19 – 21, 2024 in London. Details are as follows:

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
globenewswire.com30 August 2024 Sentiment: POSITIVE

NAARDEN, The Netherlands and MIAMI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
globenewswire.com26 July 2024 Sentiment: POSITIVE

NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced it will report topline data from the Company's Phase 3 BROOKLYN clinical trial (NCT05425745) on Monday, July 29, 2024.

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
globenewswire.com08 July 2024 Sentiment: POSITIVE

-- Company expects to report topline data in the first quarter of 2025 -- -- Company expects to report topline data in the first quarter of 2025 --

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
GlobeNewsWire25 March 2024 Sentiment: POSITIVE

NAARDEN, the Netherlands and MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present additional data from the Phase 2 ROSE2 clinical trial at the 2024 American College of Cardiology Congress (“ACC”) in Atlanta, Georgia, being held April 6-8. ROSE2 evaluated obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy; full results from the trial were previously presented at the National Lipid Association Scientific Sessions in June 2023. At ACC, NewAmsterdam will share new data demonstrating obicetrapib and ezetimibe's impact on small dense LDL-C, a robust predictor of residual risk of future cardiovascular events.

NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up
Zacks Investment Research13 March 2024 Sentiment: POSITIVE

NewAmsterdam (NAMS) gains on the initiation of a phase III study evaluating fixed-dose combination of obicetrapib and ezetimibe in patients with HeFH and/or ASCVD.

NewAmsterdam Pharma's Pioneering Pulse On Alzheimer's Breakthroughs
Seeking Alpha02 October 2023 Sentiment: POSITIVE

New clinical data shows the potential of obicetrapib in treating early Alzheimer's disease in patients with the ApoE4 mutation. The Phase IIa trial demonstrated positive biomarker indications and good safety profiles for obicetrapib. NewAmsterdam Pharma's venture into Alzheimer's research could be an undervalued growth avenue, but there are risks and the investment balance between cardiovascular studies and Alzheimer's research is crucial.

NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
GlobeNewsWire20 September 2023 Sentiment: NEUTRAL

NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma, will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023 at 1:50 p.m. ET.

NewAmsterdam Pharma: Best Cardiovascular Biotech In 2023
Seeking Alpha19 August 2023 Sentiment: POSITIVE

NewAmsterdam Pharma showcased positive trajectory in Q2 2023 financial report, with over-enrollment in obicetrapib's Ph.3 BROADWAY trial indicating robust global demand. Lead asset obicetrapib is set to present top-line data in 2H24, with potential approval by 2025-2026. Obicetrapib is a novel oral LDL-c lowering treatment that can be taken with statins and ezetimibe, which we believe to have a peak sales of ~$2bn.

After Plunging -16.36% in 4 Weeks, Here's Why the Trend Might Reverse for NewAmsterdam Pharma Company N.V. (NAMS)
Zacks Investment Research08 June 2023 Sentiment: POSITIVE

NewAmsterdam Pharma Company N.V. (NAMS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

What type of business is NewAmsterdam Pharma Company NV Ordinary Shares?

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

What sector is NewAmsterdam Pharma Company NV Ordinary Shares in?

NewAmsterdam Pharma Company NV Ordinary Shares is in the Healthcare sector

What industry is NewAmsterdam Pharma Company NV Ordinary Shares in?

NewAmsterdam Pharma Company NV Ordinary Shares is in the Biotechnology industry

What country is NewAmsterdam Pharma Company NV Ordinary Shares from?

NewAmsterdam Pharma Company NV Ordinary Shares is headquartered in Netherlands

When did NewAmsterdam Pharma Company NV Ordinary Shares go public?

NewAmsterdam Pharma Company NV Ordinary Shares initial public offering (IPO) was on 09 February 2021

What is NewAmsterdam Pharma Company NV Ordinary Shares website?

https://www.newamsterdampharma.com

Is NewAmsterdam Pharma Company NV Ordinary Shares in the S&P 500?

No, NewAmsterdam Pharma Company NV Ordinary Shares is not included in the S&P 500 index

Is NewAmsterdam Pharma Company NV Ordinary Shares in the NASDAQ 100?

No, NewAmsterdam Pharma Company NV Ordinary Shares is not included in the NASDAQ 100 index

Is NewAmsterdam Pharma Company NV Ordinary Shares in the Dow Jones?

No, NewAmsterdam Pharma Company NV Ordinary Shares is not included in the Dow Jones index

When was NewAmsterdam Pharma Company NV Ordinary Shares the previous earnings report?

No data

When does NewAmsterdam Pharma Company NV Ordinary Shares earnings report?

The next expected earnings date for NewAmsterdam Pharma Company NV Ordinary Shares is 28 February 2025